IMA - Imagenebio, Inc.

Insider Purchase by Stampacchia Otello (Dir)

1 Year
After Trade
Before Trade

Loading data...

Trade Summary

7 months ago, Stampacchia Otello, serving as Dir at Imagenebio, Inc. (IMA), purchased 267,556 shares at $29.90 per share, for a total transaction value of $7,999,924.00. Following this transaction, Stampacchia Otello now holds 455,361 shares of IMA.

This purchase represents a 142.00% increase in Stampacchia Otello's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Friday, July 25, 2025 and publicly disclosed via SEC Form 4 filing on Wednesday, July 30, 2025, 5 days after the trade was made.

Imagenebio, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Stampacchia Otello

Dir

Otello Stampacchia, Ph.D. is the founder and Managing Director of Omega Funds, a Boston-based biotech and medical device investment firm he established in 2004 (now with over $1 billion under management).[[1]](https://www.biospace.com/essa-appoints-otello-stampacchia-ph-d-of-omega-funds-to-board-of-directors)[[5]](https://www.bio.org/events/bio-investor-forum/speakers/1244245)[[7]](https://timmermanreport.com/2020/09/becoming-a-biotech-vc-otello-stampacchia-on-the-long-run/)[[10]](https://omegafunds.com/team/otello-stampacchia/) He leads investor relations, strategic initiatives, and serves on the investment committee, focusing on oncology, rare diseases, and inflammatory disorders; his career includes roles at Goldman Sachs in healthcare corporate finance and M&A (London and New York), portfolio manager of the Lombard Odier Immunology Fund, life sciences investments at AlpInvest Partners, and co-founding healthcare investments at Index Securities (now Index Ventures).[[1]](https://www.biospace.com/essa-appoints-otello-stampacchia-ph-d-of-omega-funds-to-board-of-directors)[[4]](https://www.youtube.com/watch?v=TOegFqyn--M)[[5]](https://www.bio.org/events/bio-investor-forum/speakers/1244245) Stampacchia holds a Ph.D. in Molecular Biology from the University of Geneva, a European Doctorate in Biotechnology, and an MSc in Genetics from the University of Pavia.[[1]](https://www.biospace.com/essa-appoints-otello-stampacchia-ph-d-of-omega-funds-to-board-of-directors)[[5]](https://www.bio.org/events/bio-investor-forum/speakers/1244245) He currently serves as a Director at ImageneBio, Inc. (IMA), Gossamer Bio, Kronos Bio, Median Technologies, Replimune, Morphic Holding, and others, with significant ownership stakes reflecting his estimated net worth exceeding $177 million as of recent filings.[[2]](https://www.gurufocus.com/insider/64654/otello-stampacchia)[[8]](https://imagenebio.com/team/otello-stampacchia-ph-d/)[[9]](https://www.tipranks.com/experts/insiders/otello-stampacchia) His board appointment at ESSA Pharmaceuticals in 2018 exemplifies his ongoing influence in biotech governance.[[1]](https://www.biospace.com/essa-appoints-otello-stampacchia-ph-d-of-omega-funds-to-board-of-directors)

View full insider profile →

Trade Price

$29.90

Quantity

267,556

Total Value

$7,999,924.00

Shares Owned

455,361

Trade Date

Friday, July 25, 2025

212 days ago

SEC Filing Date

Wednesday, July 30, 2025

Filed 5 days after trade

HEALTHCAREBIOTECHNOLOGY

About Imagenebio, Inc.

Company Overview

No company information available
View news mentioning IMA

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/92022

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime